Cosmetic Topical Peptides Cluster
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
How can it help me?
These are cosmetic peptides — formulated into serums and creams and applied to the skin or scalp, not reconstituted and injected. They fall into a few families: “topical Botox” relaxers that soften expression lines (Argireline, SNAP-8 and others), collagen-signaling peptides that nudge your skin to make more collagen (Matrixyl, Syn-Coll), copper peptides for repair and hair (the GHK family), and brightening peptides for dark spots.
Honest read: these are low-risk topicals with real but modest cosmetic evidence — and the closest injectable OHM actually sells is GHK-Cu.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
What should I avoid combining — and what's synergistic?
Because these are topical and low-dose, combining concerns are minimal — the usual rule is to patch-test a new serum and not pile several strong actives on at once. A few entries here (PGPIPN, DS5, Vesilute) aren't really topical cosmetics and are flagged honestly in the detail below.
How can I buy this?
We don't have a verified affiliate source for Cosmetic Topical Peptides Cluster yet, so there's no coupon or vendor link here — we won't point you to a seller we haven't vetted. When buying any research-use-only peptide, the single biggest variable is the supply chain: insist on a vendor that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity. Working with a peptide-literate clinician is one solid route — see our provider directory — or check back as our verified sources list grows.
Why this is a cluster article
These nineteen peptides share one defining trait: they are topical, cosmetic-grade actives — formulated into serums and creams, applied to the skin or scalp, not injected. That separates them cleanly from the rest of the OHM knowledge base, which is built around injectable/systemic peptide therapy. Nobody reconstitutes Argireline in BAC water and draws it into an insulin syringe; it goes into a face serum at 5–10%. So instead of nineteen thin standalone pages, they get one reference article: what each one is, how it’s claimed to work, what the evidence actually shows, and an honest read on where it stands.
They fall into a few clean mechanism families:
- Neuromuscular “Botox-like” relaxers — Argireline, SNAP-8, Vialox, Syn-Ake, Pentapeptide-18. These interrupt the nerve-to-muscle signal that drives expression lines (forehead, crow’s feet, frown lines). The marketing shorthand is “topical Botox.”
- Matrikine / collagen-signaling peptides — Matrixyl, Syn-Coll, Rigin, Tripeptide-29, Palmitoyl Dipeptide-6. These mimic collagen-breakdown fragments or other dermal signals to nudge fibroblasts toward making more collagen and extracellular matrix.
- Copper peptides and GHK derivatives — GHK (free-base), Pal-GHK, AHK-Cu, Pal-AHK. The copper-peptide / glycyl-histidyl-lysine family — skin remodeling, wound repair, and (for the AHK pair) hair-follicle support. This is the family that overlaps the injectable catalog: GHK-Cu is the injectable copper peptide OHM/Alyve actually sells.
- Pigment / brightening peptides — Decapeptide-12, Nonapeptide-1. Tyrosinase and melanin-pathway modulators for melasma, dark spots, and uneven tone.
- Other actives — PGPIPN, DS5, Vesilute. These three are in the directory but are not really topical cosmetic peptides; they’re flagged honestly below.
Commercial framing (read this first). None of these nineteen is in Alyve’s 15-SKU injectable launch catalog: Alyve sells injectable peptides, and these are topical cosmetics. So this article is encyclopedia / topical-authority content: it builds OHM’s SEO footprint and credibility on “cosmetic peptides,” a high-search-volume space, without pretending Alyve sells a product it doesn’t. The one real commercial bridge is the copper-peptide family: the injectable GHK-Cu and the GLOW blend (BPC-157 / TB-500 / GHK-Cu) are the SKUs that overlap this topic, and the OHM-15 coupon applies to those — surfaced in the copper section below, not bolted onto peptides Alyve doesn’t carry.
Quick-reference table
| Peptide | Family | Claimed action | OHM tier | Builder status | Evidence depth |
|---|---|---|---|---|---|
| Argireline (Acetyl Hexapeptide-3) | Neuro-relaxer | SNAP-25 competitor → less ACh release | C / green | recommend-eligible | Anecdotal; small topical RCTs per 0035 |
| SNAP-8 (Acetyl Octapeptide-3) | Neuro-relaxer | SNARE-complex inhibitor | D / green | provisional (encyclopedia-only) | Anecdotal (0 studies on profile) |
| Vialox (Pentapeptide-3) | Neuro-relaxer | post-synaptic ACh-receptor antagonist | D / green | provisional (encyclopedia-only) | Anecdotal (0 studies) |
| Syn-Ake | Neuro-relaxer | Waglerin-1 mimetic; nAChR antagonist | C / green | recommend-eligible | Anecdotal; 1 in-silico/in-vitro study |
| Pentapeptide-18 (Leuphasyl) | Neuro-relaxer | enkephalin mimetic → less catecholamine release | D / green | provisional (encyclopedia-only) | Emerging; 1 non-RCT human study |
| Matrixyl (Palmitoyl Pentapeptide-4) | Matrikine | mimics collagen fragment → fibroblast signaling | C / green | recommend-eligible | Moderate; 7 studies, 1 human (off-target RCT) |
| Syn-Coll (Palmitoyl Tripeptide-5) | Matrikine | thrombospondin-1 mimetic → TGF-β / collagen | D / green | provisional (encyclopedia-only) | Anecdotal (0 studies) |
| Rigin (Palmitoyl Tetrapeptide-7) | Matrikine / anti-inflammaging | IL-6 suppression in skin | C / green | recommend-eligible | Emerging; 14 studies, 0 on-target human |
| Tripeptide-29 | Matrikine | Gly-Pro-Hyp collagen-motif signal | D / green | provisional (encyclopedia-only) | Anecdotal (0 studies) |
| Palmitoyl Dipeptide-6 | Matrikine / retinol-alt | retinoid-like signaling without retinoid receptor | D / green | provisional (encyclopedia-only) | Anecdotal (0 studies) |
| GHK (free-base) | Copper family | gene-expression modulation; collagen/GAG | B / green | recommend-eligible ( + SECONDARY heal-recover) | Moderate; 30 studies, human + animal |
| Pal-GHK (Palmitoyl Tripeptide-1) | Copper family | lipidated GHK → better penetration; TGF-β | C / green | recommend-eligible | Emerging; 3 studies, 1 human (review) |
| AHK-Cu | Copper family | copper peptide; follicle / keratinocyte support | D / green | provisional (encyclopedia-only) | Anecdotal (0 studies) |
| Pal-AHK | Copper family | lipidated AHK → follicle / VEGF | D / green | provisional (encyclopedia-only) | Anecdotal (0 studies) |
| Decapeptide-12 (Lumixyl) | Pigment | tyrosinase inhibition → less melanin | C / green | recommend-eligible | Moderate; 4 studies, 3 human |
| Nonapeptide-1 (Melanostatine) | Pigment | α-MSH / MC1R antagonist → less melanin | C / green | recommend-eligible | Moderate; 4 studies, 1 RCT |
| PGPIPN | Other (not cosmetic) | milk-derived; immune/anti-cancer preclinical | D / pending | provisional (encyclopedia-only) | Emerging; 3 preclinical, anti-cancer |
| DS5 | Other (unclear) | mechanism unidentified | D / pending | provisional, no goal mapping | Profile data appears mismatched |
| Vesilute | Other (Khavinson) | vascular bioregulator (not a topical) | D / pending | provisional (encyclopedia-only) | Anecdotal (0 studies) |
Tier key (from OHM doctrine): A = human RCT/FDA · B = strong preclinical + some human · C = anecdotal/weak human · D = insufficient/marketed-but-unproven. Tiers are transparency labels, not a verdict on whether something works. Safety “green” across this cluster reflects that topical-only delivery has a benign safety record — these are applied to skin, not injected.
Neuromuscular "Botox-like" relaxers
These peptides target the neuromuscular junction — the synapse where a nerve tells a facial muscle to contract. Repeated muscle contraction is what etches dynamic expression lines (forehead lines, crow’s feet, glabellar/frown lines) into the skin over time. Injectable botulinum toxin blocks that signal at the muscle; these peptides aim to dampen the same signal cosmetically, from a topical serum. The honest catch for the whole family: topical peptides are large molecules with limited dermal penetration, so the real-world effect is far gentler than an injection — softening, not paralysis.
Argireline (Acetyl Hexapeptide-3)
The original and best-known “topical Botox” peptide. Mechanism: competes with SNAP-25 for its position in the SNARE complex, reducing vesicle docking and acetylcholine release at the neuromuscular junction, so the muscle contracts less intensely (per the profile). Evidence: the peptidelist profile lists zero PubMed studies and zero human trials and grades it Anecdotal — but OHM’s own 0035 pass graded it Tier C / green and promoted it to recommend-eligible, on the basis of “small human topical RCTs in wrinkle-depth reduction (~10–30% on facial wrinkles over 4–8 weeks)” (per 0035, manufacturer Lubrizol). That manufacturer-study gap vs. the public PubMed record is itself the content angle: the data exists but is largely industry-held. Typical cosmetic use: 5–10% in leave-on serums. Honest status: the most-used cosmetic neuro-peptide; gentle real-world effect; the headline percentages come from formulator trials, not independent PubMed RCTs.
SNAP-8 (Acetyl Octapeptide-3)
Marketed as a longer, “more potent” Argireline. Mechanism: inhibits SNARE-complex formation, reducing neurotransmitter release and muscle contraction for expression-line reduction. Evidence: profile grade Anecdotal: 0 studies, 0 human trials. 0035 keeps it Tier D / provisional (encyclopedia-only): “cosmetic-marketing-grade evidence only … no meaningful published RCT base.” Status: plausible by mechanism, marketed as an Argireline upgrade, but the published evidence is thin — encyclopedia entry, not a recommendation.
Vialox (Pentapeptide-3)
Mechanism: competitively antagonizes the acetylcholine receptor at the post-synaptic membrane, reducing muscle depolarization and contraction. Same end goal as Syn-Ake but a different target site on the junction. Evidence: Anecdotal: 0 studies, 0 human trials; 0035 Tier D / provisional. Status: cosmetic-marketing-grade only; honest encyclopedia entry.
Syn-Ake
The “snake-venom cream” ingredient. Mechanism: mimics Waglerin-1, a peptide from temple-viper venom, to competitively antagonize nicotinic acetylcholine receptors (nAChR) at the neuromuscular junction, reducing contraction frequency. Evidence: profile grade Anecdotal, with a single study — “Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests” (Gok et al., 2024, PMID 37349941) — and no human trials. OHM graded it Tier C / green and recommend-eligible on the basis of small topical RCTs reporting a muscle-relaxant effect on expression lines (per 0035, Pentapharm/DSM). Status: strong marketing story (venom mimetic), real but shallow data; OHM’s 0035 read is more favorable than the bare PubMed record.
Pentapeptide-18 (Leuphasyl)
The relaxer with the most actual human signal in this group. Mechanism: mimics enkephalin to bind opioid receptors on pre-synaptic neurons, reducing calcium influx and catecholamine release → less muscle contraction. Commonly stacked with Argireline and SNAP-8 (claimed synergy). Evidence: profile grade Emerging: 4 studies, 1 human (non-RCT). The one human-relevant study is a retinol + oligopeptide nanocarrier cohort reporting reduced sebum and facial wrinkles with improved tolerability (Pawłowska et al., 2024, PMID 39459512); the rest are in-vitro/computational (e.g. PMID 39337562, PMID 31937863, both). Despite that human study, 0035 kept it Tier D / provisional — the human study tests it combined with retinol in a nanocarrier, so it doesn’t isolate the peptide’s own effect. Status: best-studied of the relaxers on paper, but the cleanest human data is confounded by co-formulation; honest encyclopedia entry.
Matrikine / collagen-signaling peptides
Matrikines are peptide fragments that the skin reads as “collagen is breaking down — make more.” By presenting a synthetic version of that fragment, these peptides aim to trick fibroblasts into ramping up collagen and extracellular-matrix (ECM) synthesis — firmer skin, less wrinkle depth. This is the “build the skin back up” half of cosmetic peptides, as opposed to the “relax the muscle” half above.
Matrixyl (Palmitoyl Pentapeptide-4)
The flagship matrikine and one of the most-formulated cosmetic peptides in the world (variants: Matrixyl 3000, Matrixyl Synthe’6). Mechanism: a matrikine that mimics collagen-breakdown fragments, signaling fibroblasts to increase synthesis of collagen I, III, IV, fibronectin, and hyaluronic acid. Evidence: profile grade Moderate: 7 studies, 1 human. Important honesty note: the one human RCT on the profile (Röper et al., 2004, Strahlenther Onkol, n=20, PMID 15127162) tested a Matrixyl-containing cream for radiation skin toxicity in breast-cancer patients and found no advantage over a comparison lotion: it is not a wrinkle-efficacy trial. The supporting collagen-stimulation data is (e.g. C16-KTTKS on fibroblasts, Jones et al., 2013, PMID 23320752). OHM grades it Tier C / green / recommend-eligible, citing the formulator wrinkle RCTs “Robinson 2005, Trookman 2009” (per 0035) that aren’t on the peptidelist profile. Typical cosmetic use: ~3–8% of the trade solution in leave-on products. Status: the best-known matrikine; mechanism well characterized in vitro; the strongest wrinkle data is industry-held, and the one public human RCT is off-target.
Syn-Coll (Palmitoyl Tripeptide-5)
Mechanism: mimics the active site of thrombospondin-1, activating latent TGF-β and triggering downstream collagen I and III synthesis in dermal fibroblasts. Evidence: Anecdotal: 0 studies, 0 human trials; 0035 Tier D / provisional. Status: clean mechanistic story (TGF-β activation), no published efficacy data — encyclopedia entry.
Rigin (Palmitoyl Tetrapeptide-7)
The “anti-inflammaging” peptide; a key ingredient in Matrixyl 3000 alongside Pal-GHK. Mechanism: suppresses IL-6 and other pro-inflammatory cytokine release from keratinocytes and immune cells, reducing the chronic low-grade inflammation (“inflammaging”) that accelerates skin aging. Evidence: profile lists 14 studies but 0 on-target human trials, graded Emerging — and most of those 14 are clearly off-target database matches (virology/MAVS-signaling papers, an antifungal-analog study), not skin studies; treat the count as profile noise, not evidence depth. OHM grades it Tier C / green / recommend-eligible as “Palmitoyl Tetrapeptide-7 (Sederma), small topical anti-inflammation skin trials.” Status: real role in marketed blends (Matrixyl 3000), plausible anti-inflammatory mechanism, but the public study list for this exact peptide is sparse and contaminated by mismatches.
Tripeptide-29
Mechanism: the Gly-Pro-Hyp motif: the most abundant repeating sequence in collagen — acts as a matrikine signal that fibroblast integrin receptors read as a collagen-degradation fragment, triggering compensatory collagen I and III synthesis. Evidence: Anecdotal: 0 studies, 0 human trials; 0035 Tier D / provisional. Status: elegant mechanistic rationale (it’s literally a fragment of collagen itself), no published efficacy data.
Palmitoyl Dipeptide-6
Marketed as a retinol alternative with less irritation. Mechanism: claimed to activate retinoid-like signaling in keratinocytes and fibroblasts: epidermal renewal and dermal matrix synthesis — without binding retinoid receptors directly. Evidence: Anecdotal: 0 studies, 0 human trials; 0035 Tier D / provisional. Status: appealing positioning (retinol benefits, no retinol irritation), entirely marketing-grade evidence at present.
Copper peptides and GHK derivatives — the family that overlaps the injectable catalog
This is the family worth knowing best, because it’s where topical cosmetics meet the injectable peptide world OHM actually sells. The parent molecule, GHK (glycyl-L-histidyl-L-lysine), is a naturally occurring human tripeptide; bound to copper it becomes GHK-Cu, the most evidence-backed peptide in skin and wound research. Alyve sells the injectable copper peptide as GHK-Cu and inside the GLOW blend — so when a reader lands on this topical-cosmetics article looking for copper peptides, the systemic copper-peptide SKU is the natural bridge.
GHK (free-base)
What it is: the non-copper-coordinated form of the GHK tripeptide (Gly-His-Lys): the base molecule behind GHK-Cu. Mechanism: modulates gene expression related to tissue remodeling, collagen synthesis, and wound healing. Evidence: the strongest in this whole cluster: profile grade Moderate, 30 studies including human and animal. Genuine on-target findings include a crow’s-feet case report with increased collagen and elastic-fiber production (Byun et al., 2016, PMID 27064823) and multiple GHK-Cu studies in wound healing, lung fibrosis, and smoking-induced muscle dysfunction (e.g. PMID 36905132, PMID 28370978, both). (Note: the profile’s #1 “RCT, n=1600” is a children’s-bodyweight intervention trial that’s an off-target database match, not a GHK study.) OHM grades free-base GHK Tier B / green / recommend-eligible ( + SECONDARY heal-recover) — “Tier B by extrapolation from the GHK-Cu literature,” noting the copper-coordinated form drives most of the documented benefit. Status: the anchor of the cosmetic-peptide world; most of the real evidence belongs to the copper form. → For the injectable copper peptide OHM/Alyve sells, see GHK-Cu and the GLOW blend.
Pal-GHK (Palmitoyl Tripeptide-1)
The lipidated, better-penetrating cosmetic form of GHK; a core ingredient in Matrixyl 3000 (paired with Rigin). Mechanism: palmitoylation adds a fatty-acid tail that improves lipophilicity and dermal penetration; activates fibroblasts via TGF-β to produce collagen, glycosaminoglycans, and elastin. Evidence: profile grade Emerging: 3 studies, the human-relevant one being a topical anti-wrinkle review (Mortazavi et al., 2025, PMID 39963574). OHM grades it Tier C / green / recommend-eligible on “small topical RCTs.” Status: the practical, penetration-optimized cosmetic version of GHK; real role in major commercial blends.
AHK-Cu
The copper peptide marketed for hair growth rather than facial skin. Mechanism: a copper-peptide complex that may stimulate hair-follicle activity and support keratinocyte proliferation. Evidence: Anecdotal: 0 studies, 0 human trials; 0035 Tier D / provisional. Status: popular in scalp/hair serums, mechanistically plausible as a copper peptide, but no published trial base for this specific molecule.
Pal-AHK
The lipidated, enhanced-penetration form of AHK for hair. Mechanism: the palmitoyl group enhances skin penetration to deliver the AHK tripeptide to hair follicles, where it may stimulate dermal papilla cells and promote VEGF expression. Evidence: Anecdotal: 0 studies, 0 human trials; 0035 Tier D / provisional. Status: the penetration-optimized hair version of AHK-Cu; same honest read — plausible, unproven for this exact peptide.
Pigment / brightening peptides
These two target the melanin pathway rather than collagen or muscle: used for melasma, dark spots, post-inflammatory hyperpigmentation, and uneven tone. Notably, this sub-group has the strongest human evidence in the entire cluster, because pigment endpoints are easy to photograph and measure in a clinic.
Decapeptide-12 (Lumixyl)
A peptide alternative to hydroquinone for skin lightening. Mechanism: inhibits the tyrosinase enzyme and reduces melanin transfer to keratinocytes, lowering melanin deposition. Evidence: the best human data in this cluster: profile grade Moderate, 4 studies, 3 human. Real on-target findings: a melasma open-label study reporting ~60% reduction in severity at 16 weeks with no adverse events (Ramírez et al., 2013, PMID 23839199), a photodamage study with 100% of subjects improving and 38.5% achieving complete clearance (Kassim et al., 2012, PMID 22401652), and a post-inflammatory-hyperpigmentation study (Bhatia et al., 2014, PMID 24385124). OHM grades it Tier C / green / recommend-eligible (Lumixyl). Status: genuinely evidenced for pigment; one of the few in this cluster with multiple on-target human studies.
Nonapeptide-1 (Melanostatine)
Mechanism: antagonizes α-MSH at the MC1R receptor on melanocytes, reducing cAMP-mediated activation of tyrosinase and downstream melanin synthesis. Evidence: profile grade Moderate, 4 studies, 1 RCT. The RCT (Chatterjee et al., 2021, Indian J Dermatol Venereol Leprol, PMID 34379946) tested a proprietary combination containing Nonapeptide-1 vs. sunscreen for melasma maintenance and found it efficacious: so the peptide is one component of the tested formula, not isolated. Supporting in-vitro work covers the α-MSH/MC1R melanogenesis pathway (e.g. PMID 35645678, PMID 39260749, both). OHM grades it Tier C / green / recommend-eligible (Mela-X / Lipotec). Status: real RCT signal for melasma maintenance, with the usual cosmetic-trial caveat that it was tested in a combination product.
Other actives (in the directory, but not topical cosmetic peptides)
These three came through the same directory but don’t actually belong to the cosmetic-skincare story. They’re documented here for completeness with an honest “this isn’t what it looks like” note.
PGPIPN
A milk-derived hexapeptide — not a skincare peptide. Mechanism / evidence: the profile (graded Emerging, 3 studies, 0 human) describes preclinical anti-cancer and immune-modulation work: inhibiting ovarian-cancer cell invasion and growth in vitro and in vivo via MTA1/NM23H1 and BCL2 pathways. OHM grades it Tier D / pending / provisional with a SECONDARY heal-recover label and “minimal published human data.” Status: an immune/oncology research peptide that landed in a cosmetic list by category drift — included here only so the cluster is complete.
DS5
Status: unclear: likely a data artifact. The profile claims 30 studies / 19 human trials, but the actual cited content is about Deauville-score PET imaging as a prognostic biomarker in lymphoma — i.e. the directory appears to have matched the string “DS5” to oncology-imaging literature, not to any peptide. 0035 reaches the same conclusion: “No clear KB or pharmacology grounding … KEPT D/pending, with no consumer-goal mapping … Encyclopedia-only with a ‘what is this?’ note.” Honest read: there is no verified cosmetic (or peptide) identity for “DS5” in our sources. Do not build content on it until the identity is resolved.
Vesilute
A Khavinson-school bioregulator, not a topical cosmetic. Mechanism: a short peptide bioregulator claimed to modulate gene expression in vascular endothelial cells, supporting vessel-wall integrity. Evidence: Anecdotal: 0 studies, 0 human trials. 0035 folds it into the Khavinson organ-peptide line (Livagen / Ovagen / Pancragen / Prostamax / etc.), all Tier D / pending / provisional, noting “Russian-school preclinical with NO meaningful Western or independent Russian human RCT data” and recommending a single framework article rather than separate pages. Status: belongs to the Khavinson bioregulator cluster, not the cosmetic-topical cluster — listed here only because it shared the source directory.
Content hooks for OHM
- “Topical Botox” explainer — the neuro-relaxer family (Argireline, SNAP-8, Vialox, Syn-Ake, Pentapeptide-18): what “Botox in a serum” really means, why topical penetration makes the effect gentle, and the manufacturer-data-vs-PubMed gap. High-search, high-credibility angle.
- “Copper peptides explained” — anchor on GHK/GHK-Cu, connect the topical cosmetic family to the injectable copper peptide and the GLOW blend OHM/Alyve sells. The natural commercial bridge from this article.
- “Which cosmetic peptides actually have human data?” — the honest-sourcing differentiator: Decapeptide-12 and Nonapeptide-1 have real human/RCT pigment data; most of the rest are mechanism + marketing. OHM as the source that tells you the difference.
- Matrixyl 3000 deconstructed — the blend is Pal-GHK + Rigin; explain what each component does and where the evidence actually sits.
Sources
- profiles (thepeptidelist.com directory, captured 2026-06-07): argireline · matrixyl · syn-ake · syn-coll · snap-8 · vialox · rigin · pentapeptide-18 · palmitoyl-dipeptide-6 · decapeptide-12 · nonapeptide-1 · tripeptide-29 · pal-ghk · pal-ahk · ahk-cu · ghk · pgpipn · ds5 · vesilute. All site-derived citations carry per KB doctrine (pending the citation-verification pass).
- OHM tier/safety/goal grading for every peptide above (Argireline/Matrixyl/Syn-Ake/Decapeptide-12/Pal-GHK/Nonapeptide-1/Rigin = C/green/recommend-eligible; GHK = B/green/recommend-eligible; the rest = D/provisional/encyclopedia-only; DS5 = unclear; Vesilute = Khavinson line).
- Cross-linked articles: GHK-Cu · GLOW · KLOW.
Sources & references
- profiles (thepeptidelist.com directory, captured 2026-06-07): argireline · matrixyl · syn-ake · syn-coll · snap-8 · vialox · rigin · pentapeptide-18 · palmitoyl-dipeptide-6 · decapeptide-12 · nonapeptide-1 · tripeptide-29 · pal-ghk · pal-ahk · ahk-cu · ghk · pgpipn · ds5 · vesilute. All site-derived citations carry per KB doctrine (pending the citation-verification pass).
- OHM tier/safety/goal grading for every peptide above (Argireline/Matrixyl/Syn-Ake/Decapeptide-12/Pal-GHK/Nonapeptide-1/Rigin = C/green/recommend-eligible; GHK = B/green/recommend-eligible; the rest = D/provisional/encyclopedia-only; DS5 = unclear; Vesilute = Khavinson line).
- Cross-linked articles: GHK-Cu · GLOW · KLOW.